NCT03534492View on ClinicalTrials.gov

Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

March 16, 2020

Study Completion Date

March 16, 2020

Conditions
Bladder Cancer
Interventions
DRUG

Durvalumab

Infusion

DRUG

Olaparib

P.O.

Trial Locations (10)

27003

Hospital Universitario Lucus Augusti, Lugo

28034

Hospital Ramón Y Cajal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

33006

Hospital Universitario Central de Asturias, Oviedo

08916

ICO Badalona, Badalona

Unknown

Clinica IMQ Zorrotzaurre, Bilbao

Hospital San Pedro de Alcántara, Cáceres

Hopsital Universitario Madrid Sanchinarro (CIOCC), Madrid

Hospital de Navarra, Pamplona

Hospital Virgen Macarena, Seville

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Sistemas Genómicos

UNKNOWN

collaborator

Apices Soluciones S.L.

INDUSTRY

lead

Spanish Oncology Genito-Urinary Group

OTHER

NCT03534492 - Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB) | Biotech Hunter | Biotech Hunter